Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer.

@article{Gershonibaruch2000SignificantlyLR,
  title={Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer.},
  author={Ruth Gershoni-baruch and Efrat Dagan and Getta Fried and R. Bruchim Bar-Sade and R Sverdlov-Shiri and G Zelicksson and Eitan Friedman},
  journal={European journal of cancer},
  year={2000},
  volume={36 8},
  pages={983-6}
}
To delineate the clinical, genetic and family history attributes in Jewish Ashkenazi women with early onset (< 42 years) breast cancer we genotyped such women for the three predominant Jewish Ashkenazi mutations in BRCA1 (185delAG and 5382insC) and BRCA2 (6174delT). The study cohort was composed of 172 women diagnosed with breast cancer at or before the age of 42 years, obtained from the oncology department registry. Mutations were identified in 54 women (31%). Of 79 women with a positive… CONTINUE READING